Literature DB >> 15496564

A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria.

Jean Francis1, Junhui Zhang, Anita Farhi, Hugh Carey, David S Geller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15496564     DOI： 10.1093/ndt/gfh426

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  14 in total

Review 1.  Sodium-glucose transport: role in diabetes mellitus and potential clinical implications.

Authors:  Volker Vallon; Kumar Sharma
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-09       Impact factor: 2.894

2.  Familial renal glucosuria: a clinicogenetic study of 23 additional cases.

Authors:  HyunKyung Lee; Kyoung Hee Han; Hye Won Park; Jae Il Shin; Chan Jong Kim; Mee Kyung Namgung; Kee Hyuck Kim; Ja Wook Koo; Woo Young Chung; Dae-Yeol Lee; Su-Yung Kim; Hae Il Cheong
Journal:  Pediatr Nephrol       Date:  2012-07       Impact factor: 3.714

3.  Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.

Authors:  Atsuo Tahara; Eiji Kurosaki; Masanori Yokono; Daisuke Yamajuku; Rumi Kihara; Yuka Hayashizaki; Toshiyuki Takasu; Masakazu Imamura; Li Qun; Hiroshi Tomiyama; Yoshinori Kobayashi; Atsushi Noda; Masao Sasamata; Masayuki Shibasaki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-12-03       Impact factor: 3.000

4.  SGLT2 mediates glucose reabsorption in the early proximal tubule.

Authors:  Volker Vallon; Kenneth A Platt; Robyn Cunard; Jana Schroth; Jean Whaley; Scott C Thomson; Hermann Koepsell; Timo Rieg
Journal:  J Am Soc Nephrol       Date:  2010-07-08       Impact factor: 10.121

5.  Abnormal expression and dysfunction of novel SGLT2 mutations identified in familial renal glucosuria patients.

Authors:  Lei Yu; Ji-Cheng Lv; Xu-jie Zhou; Li Zhu; Ping Hou; Hong Zhang
Journal:  Hum Genet       Date:  2010-12-17       Impact factor: 4.132

Review 6.  Pathophysiology of the diabetic kidney.

Authors:  Volker Vallon; Radko Komers
Journal:  Compr Physiol       Date:  2011-07       Impact factor: 9.090

7.  SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.

Authors:  Volker Vallon; Maria Gerasimova; Michael A Rose; Takahiro Masuda; Joseph Satriano; Eric Mayoux; Hermann Koepsell; Scott C Thomson; Timo Rieg
Journal:  Am J Physiol Renal Physiol       Date:  2013-11-13

8.  High glucose-induced Smad3 linker phosphorylation and CCN2 expression are inhibited by dapagliflozin in a diabetic tubule epithelial cell model.

Authors:  Xinlu Pan; Mysore K Phanish; Deborah L Baines; Mark E C Dockrell
Journal:  Biosci Rep       Date:  2021-06-25       Impact factor: 3.840

9.  SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function.

Authors:  Michael J Jurczak; Hui-Young Lee; Andreas L Birkenfeld; Francois R Jornayvaz; David W Frederick; Rebecca L Pongratz; Xiaoxian Zhao; Gilbert W Moeckel; Varman T Samuel; Jean M Whaley; Gerald I Shulman; Richard G Kibbey
Journal:  Diabetes       Date:  2011-03       Impact factor: 9.461

10.  Clinical and genetic analysis in a patient with primary renal glucosuria: Identification of a novel mutation in the SLC5A2 gene.

Authors:  Yong-Wha Lee
Journal:  Exp Ther Med       Date:  2013-10-04       Impact factor: 2.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.